Mechanisms involved in the development of thrombocytopenia in patients with COVID-19.

Authors :: Zhang Y
Zeng X
Jiao Y
Li Z
Liu Q
Ye J
Yang M
Source :: Thrombosis research [Thromb Res] 2020 Sep; Vol. 193, pp. 110-115. Date of Electronic Publication: 2020 Jun 05.
Publication Year :: 2020
Abstract: Corona Virus Disease 2019 (COVID-19) is caused by the novel coronavirus SARS-CoV-2. Emerging genetic and clinical evidence suggests similarities between COVID-19 patients and those with severe acute respiratory syndrome and Middle East respiratory syndrome. Hematological changes such as lymphopenia and thrombocytopenia are not rare in COVID-19 patients, and a smaller population of these patients had leukopenia. Thrombocytopenia was detected in 5-41.7% of the patients with COVID-19. Analyzing the dynamic decrease in platelet counts may be useful in the prognosis of patients with COVID-19. However, the mechanisms underlying the development of thrombocytopenia remain to be elucidated. This review summarizes the hematological changes in patients infected with SARS-CoV-2 and possible underlying mechanisms of thrombocytopenia development.<br />Competing Interests: Declaration of competing interest There are no conflicts of interest to declare.<br /> (Copyright © 2020. Published by Elsevier Ltd.)

Full Text Access

Tools